These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 37967254)

  • 41. The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.
    Dagnew AF; Klein NP; Hervé C; Kalema G; Di Paolo E; Peterson J; Salaun B; Schuind A
    J Infect Dis; 2021 Oct; 224(7):1139-1146. PubMed ID: 32103273
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
    Goud R; Lufkin B; Duffy J; Whitaker B; Wong HL; Liao J; Lo AC; Parulekar S; Agger P; Anderson SA; Wernecke M; MaCurdy TE; Weintraub E; Kelman JA; Forshee RA
    JAMA Intern Med; 2021 Dec; 181(12):1623-1630. PubMed ID: 34724025
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT).
    Curran D; Matthews S; Rowley SD; Young JH; Bastidas A; Anagnostopoulos A; Barista I; Chandrasekar PH; Dickinson M; El Idrissi M; Heras I; Milliken ST; Monserrat Coll J; Navarro Matilla MB; Oostvogels L; Piątkowska-Jakubas B; Quiel D; Sabry W; Schwartz S; Selleslag DLD; Sullivan KM; Theunissen K; Yegin ZA; Yeh SP; Zaja F; Szer J;
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2474-2481. PubMed ID: 31394276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019.
    Patterson BJ; Chen CC; McGuiness CB; Glasser LI; Sun K; Buck PO
    Hum Vaccin Immunother; 2021 Aug; 17(8):2482-2487. PubMed ID: 33849373
    [No Abstract]   [Full Text] [Related]  

  • 45. Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study.
    Sun Y; Jackson K; Dalmon CA; Shapiro BL; Nie S; Wong C; Arnold BF; Porco TC; Acharya NR
    Vaccine; 2021 Jun; 39(29):3974-3982. PubMed ID: 34116874
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
    Hastie A; Catteau G; Enemuo A; Mrkvan T; Salaun B; Volpe S; Smetana J; Rombo L; Schwarz T; Pauksens K; Hervé C; Bastidas A; Schuind A
    J Infect Dis; 2021 Dec; 224(12):2025-2034. PubMed ID: 32502272
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview.
    Dagnew AF; Vink P; Drame M; Willer DO; Salaun B; Schuind AE
    Hum Vaccin Immunother; 2021 Nov; 17(11):4132-4143. PubMed ID: 34190658
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis.
    McGirr A; Widenmaier R; Curran D; Espié E; Mrkvan T; Oostvogels L; Simone B; McElhaney JE; Burnett H; Haeussler K; Thano A; Wang X; Newson RS
    Vaccine; 2019 May; 37(22):2896-2909. PubMed ID: 30982636
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial.
    Vink P; Ramon Torrell JM; Sanchez Fructuoso A; Kim SJ; Kim SI; Zaltzman J; Ortiz F; Campistol Plana JM; Fernandez Rodriguez AM; Rebollo Rodrigo H; Campins Marti M; Perez R; González Roncero FM; Kumar D; Chiang YJ; Doucette K; Pipeleers L; Agüera Morales ML; Rodriguez-Ferrero ML; Secchi A; McNeil SA; Campora L; Di Paolo E; El Idrissi M; López-Fauqued M; Salaun B; Heineman TC; Oostvogels L;
    Clin Infect Dis; 2020 Jan; 70(2):181-190. PubMed ID: 30843046
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
    Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M
    Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions.
    Sullivan KM; Farraye FA; Winthrop KL; Willer DO; Vink P; Tavares-Da-Silva F
    Vaccine; 2023 Jan; 41(1):36-48. PubMed ID: 36460534
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis.
    Mbinta JF; Nguyen BP; Awuni PMA; Paynter J; Simpson CR
    Lancet Healthy Longev; 2022 Apr; 3(4):e263-e275. PubMed ID: 36098300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccination for quality of life: herpes-zoster vaccines.
    Lang PO; Aspinall R
    Aging Clin Exp Res; 2021 Apr; 33(4):1113-1122. PubMed ID: 31643072
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50-64 years in the United States.
    Leung J; Gray EB; Anderson TC; Sharkey SM; Dooling K
    Vaccine; 2022 Nov; 40(50):7187-7190. PubMed ID: 36347721
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vaccines for preventing herpes zoster in older adults.
    Gagliardi AM; Andriolo BN; Torloni MR; Soares BG
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD008858. PubMed ID: 26937872
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials.
    Kim JH; Diaz-Decaro J; Jiang N; Hwang SJ; Choo EJ; Co M; Hastie A; Hui DSC; Irimajiri J; Lee J; Leung EM; Tang H; Tsuru T; Watson P; Wu Z; Yu CJ; Yuan Y; Zahaf T; Cunningham AL; Schuind A
    Hum Vaccin Immunother; 2021 Jul; 17(7):2050-2057. PubMed ID: 33606577
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults.
    Janusz CB; Anderson TC; Leidner AJ; Lee GM; Dooling K; Prosser LA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2060668. PubMed ID: 35476029
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing.
    Lee C; Jiang N; Tang H; Ye C; Yuan Y; Curran D
    Hum Vaccin Immunother; 2021 Oct; 17(10):3735-3746. PubMed ID: 34310268
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials.
    Dagnew AF; Rausch D; Hervé C; Zahaf T; Levin MJ; Schuind A;
    Rheumatology (Oxford); 2021 Mar; 60(3):1226-1233. PubMed ID: 32910152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data.
    Lewis CY; Mishra K; Sun Y; Sechrist SJ; Arnold BF; Acharya NR
    Vaccine; 2023 May; 41(23):3493-3496. PubMed ID: 37150621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.